{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T16:02:43Z","timestamp":1780761763322,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T00:00:00Z","timestamp":1775952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T00:00:00Z","timestamp":1775952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intrahepatic cholangiocarcinoma (iCCA) is a rare liver malignancy with poor prognosis. This study assessed how case discussion of patients at expert centers within multidisciplinary team meetings (MDTs) is associated with treatment and survival in iCCA patients in the Netherlands.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study analyzed data registered in the Netherlands Cancer Registry between 2017 and 2021 on all consecutive patients diagnosed with iCCA. Data included patient demographics, tumor characteristics, and the involvement of a member of an expert center at case discussions. Outcomes included overall survival and treatment type, which was specified as tumor-directed (e.g., resection, ablation, systemic treatment, or other treatment modalities) vs. supportive care only.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 1.622 patients included, median overall survival was 5.4 months, and 825 (50.9%) underwent tumor-directed therapy. Patients discussed at expert centers (59.6%) were more likely to receive tumor-directed therapy (58.8% vs. 37.2%,\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001) and undergo surgery (20.3% vs. 5.7%,\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). In the multivariable analysis, patients discussed at expert centers had better overall survival (hazard ratio 0.69 (0.62\u20130.78)).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Centralized care through MDT discussion at expert centers was associated with increased likelihood of receiving tumor-directed therapy and improved survival in iCCA patients. This study highlights the potential for improved patient outcomes through structured expert consultations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-19540-1","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T18:27:04Z","timestamp":1776018424000},"page":"6090-6098","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Case Discussion with Expert Centers on Treatment Outcome of Intrahepatic Cholangiocarcinoma"],"prefix":"10.1245","volume":"33","author":[{"given":"Thomas C.","family":"Zwaan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Buettner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia G.","family":"van der Geest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Verheij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andries E.","family":"Braat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris I.","family":"Erdmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Hagendoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"de Vos-Geelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Groot Koerkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim B.","family":"Olthof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Dutch Hepatocellular and Cholangiocarcinoma Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,12]]},"reference":[{"key":"19540_CR1","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2147\/OTT.S93629","volume":"10","author":"S Buettner","year":"2017","unstructured":"Buettner S, van Vugt JL, JN IJ, Groot Koerkamp B. Intrahepatic cholangiocarcinoma: current perspectives. Onco Targets Ther. 2017;10:1131\u201342.","journal-title":"Onco Targets Ther."},{"key":"19540_CR2","unstructured":"IKNL. Levercel- en galwegkanker in Nederland. 2023; https:\/\/iknl.nl\/getmedia\/487ed4b8-4b77-4672-b4e5-bc6de00a26f4\/HPB_levercel-en-galwegkanker_def.pdf. Accessed 25-04-2024."},{"issue":"4","key":"19540_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s13304-015-0330-3","volume":"67","author":"M Massani","year":"2015","unstructured":"Massani M, Nistri C, Ruffolo C, et al. Intrahepatic chemotherapy for unresectable cholangiocarcinoma: review of literature and personal experience. Updates Surg. 2015;67(4):389\u2013400.","journal-title":"Updates Surg."},{"issue":"11","key":"19540_CR4","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.hpb.2023.06.019","volume":"25","author":"PB Olthof","year":"2023","unstructured":"Olthof PB, Franssen S, van Keulen AM, et al. Nationwide treatment and outcomes of intrahepatic cholangiocarcinoma. HPB (Oxford). 2023;25(11):1329\u201336.","journal-title":"HPB (Oxford)."},{"key":"19540_CR5","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1200\/EDBK_236857","volume":"39","author":"P Selby","year":"2019","unstructured":"Selby P, Popescu R, Lawler M, Butcher H, Costa A. The value and future developments of multidisciplinary team cancer care. Am Soc Clin Oncol Educ Book. 2019;39:332\u201340.","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"19540_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ctrv.2015.11.007","volume":"42","author":"B Pillay","year":"2016","unstructured":"Pillay B, Wootten AC, Crowe H, et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. Cancer Treat Rev. 2016;42:56\u201372.","journal-title":"Cancer Treat Rev."},{"key":"19540_CR7","doi-asserted-by":"publisher","first-page":"107327482110099","DOI":"10.1177\/10732748211009945","volume":"28","author":"AY Jia","year":"2021","unstructured":"Jia AY, Popovic A, Mohan AA, et al. Development, practice patterns, and early clinical outcomes of a multidisciplinary liver cancer clinic. Cancer Control. 2021;28:10732748211009944.","journal-title":"Cancer Control."},{"issue":"2","key":"19540_CR8","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.3747\/co.20.1297","volume":"20","author":"J Zhang","year":"2013","unstructured":"Zhang J, Mavros MN, Cosgrove D, et al. Impact of a single-day multidisciplinary clinic on the management of patients with liver tumours. Curr Oncol. 2013;20(2):e123\u201331.","journal-title":"Curr Oncol."},{"issue":"5","key":"19540_CR9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","volume":"19","author":"AB Benson","year":"2021","unstructured":"Benson AB, D\u2019Angelica MI, Abbott DE, et al. Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(5):541\u201365.","journal-title":"J Natl Compr Canc Netw."},{"issue":"2","key":"19540_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127\u201340.","journal-title":"Ann Oncol."},{"issue":"20","key":"19540_CR11","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1002\/cncr.34436","volume":"128","author":"YT Lee","year":"2022","unstructured":"Lee YT, Singal AG, Lauzon M, et al. Disparities in curative treatments and outcomes for early stage intrahepatic cholangiocarcinoma in the United States. Cancer. 2022;128(20):3610\u20139.","journal-title":"Cancer."},{"issue":"8","key":"19540_CR12","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1111\/liv.14856","volume":"41","author":"AM van Keulen","year":"2021","unstructured":"van Keulen AM, Franssen S, van der Geest LG, et al. Nationwide treatment and outcomes of perihilar cholangiocarcinoma. Liver Int. 2021;41(8):1945\u201353.","journal-title":"Liver Int."},{"issue":"13","key":"19540_CR13","doi-asserted-by":"publisher","first-page":"8152","DOI":"10.1245\/s10434-021-10650-6","volume":"28","author":"TL Sutton","year":"2021","unstructured":"Sutton TL, Walker BS, Nabavizadeh N, et al. Geographic disparities in referral rates and oncologic outcomes of intrahepatic cholangiocarcinoma: a population-based study. Ann Surg Oncol. 2021;28(13):8152\u20139.","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"19540_CR14","doi-asserted-by":"publisher","first-page":"4813","DOI":"10.1245\/s10434-023-13567-4","volume":"30","author":"KE Rhodin","year":"2023","unstructured":"Rhodin KE, Liu A, Bartholomew A, et al. Trends in receipt of adjuvant chemotherapy and its impact on survival in resected biliary tract cancers. Ann Surg Oncol. 2023;30(8):4813\u201321.","journal-title":"Ann Surg Oncol."},{"key":"19540_CR15","doi-asserted-by":"publisher","first-page":"100324","DOI":"10.1016\/j.lanepe.2022.100324","volume":"15","author":"C Neuzillet","year":"2022","unstructured":"Neuzillet C, Emery C, Teissier C, Bouee S, Lievre A. Patient healthcare trajectories of intrahepatic cholangiocarcinoma in France: A nationwide retrospective analysis. Lancet Reg Health Eur. 2022;15:100324.","journal-title":"Lancet Reg Health Eur."},{"issue":"2","key":"19540_CR16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.surg.2023.10.034","volume":"175","author":"YX Koh","year":"2024","unstructured":"Koh YX, Zhao Y, Tan IE, et al. The impact of hospital volume on liver resection: A systematic review and Bayesian network meta-analysis. Surgery. 2024;175(2):393\u2013403.","journal-title":"Surgery."},{"issue":"5","key":"19540_CR17","doi-asserted-by":"publisher","first-page":"292","DOI":"10.35772\/ghm.2020.01013","volume":"2","author":"E Franchi","year":"2020","unstructured":"Franchi E, Donadon M, Torzilli G. Effects of volume on outcome in hepatobiliary surgery: a review with guidelines proposal. Glob Health Med. 2020;2(5):292\u20137.","journal-title":"Glob Health Med."},{"issue":"11","key":"19540_CR18","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1007\/s11605-013-2314-2","volume":"17","author":"AJ Richardson","year":"2013","unstructured":"Richardson AJ, Pang TC, Johnston E, Hollands MJ, Lam VW, Pleass HC. The volume effect in liver surgery\u2013a systematic review and meta-analysis. J Gastrointest Surg. 2013;17(11):1984\u201396.","journal-title":"J Gastrointest Surg."},{"issue":"3","key":"19540_CR19","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.hpb.2018.08.004","volume":"21","author":"A Kommalapati","year":"2019","unstructured":"Kommalapati A, Tella SH, Goyal G, et al. Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma. HPB (Oxford). 2019;21(3):379\u201386.","journal-title":"HPB (Oxford)."},{"issue":"1","key":"19540_CR20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/jso.27102","volume":"127","author":"MM Munir","year":"2023","unstructured":"Munir MM, Alaimo L, Moazzam Z, et al. Textbook oncologic outcomes and regionalization among patients undergoing hepatic resection for intrahepatic cholangiocarcinoma. J Surg Oncol. 2023;127(1):81\u20139.","journal-title":"J Surg Oncol."},{"issue":"7","key":"19540_CR21","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s00268-019-04966-4","volume":"43","author":"L Wu","year":"2019","unstructured":"Wu L, Tsilimigras DI, Paredes AZ, et al. Trends in the incidence, treatment and outcomes of patients with intrahepatic cholangiocarcinoma in the USA: Facility type is associated with margin status, use of lymphadenectomy and overall survival. World J Surg. 2019;43(7):1777\u201387.","journal-title":"World J Surg."},{"issue":"12","key":"19540_CR22","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1245\/s10434-019-07657-5","volume":"26","author":"GC Lee","year":"2019","unstructured":"Lee GC, Gamblin TC, Fong ZV, et al. Facility type is associated with margin status and overall survival of patients with resected intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2019;26(12):4091\u20139.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19540-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19540-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19540-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:52:06Z","timestamp":1780761126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19540-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,12]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["19540"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19540-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,12]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None of the authors on this paper have commercial interests in relation to the contents of this paper. Furthermore, there was no financial or material support for this paper.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosuer"}}]}}